Table 4.

Evaluation of SU11248 combined with docetaxel compared with monotherapies against established human breast cancer 435/HAL-Luc growth in bone of athymic mice

AgentaDose (mg/kg)nMDS ± SEM (days)Difference between means (P-value) χ2 test: difference in survival on designated day (P-value)
ControlN/A1646 ± 2N/A
SU11248401552 ± 20.02
Docetaxel51352 ± 10.02
SU11248 + docetaxel40 + 51560 ± 20.0001Day 61 vs. SU11248: 0.0002
vs. SU11248: 0.005
vs. Docetaxel: 0.0007
  • a SU11248 given p.o. once daily to study end; docetaxel given i.v. once weekly for 3 weeks.